As director of Pew's prescription drug abuse project, Reilly works on federal and state initiatives to reduce the health and economic consequences of prescription drug abuse.
Prior to joining Pew, Reilly worked on issues related to the safety and quality of medication use for the American Society of Health-System Pharmacists in Bethesda, Maryland. Areas of focus included the development of clinical policy, dissemination of best practices to improve patient outcomes, and coordination of initiatives aimed at ensuring the availability and integrity of drug products. In this role, she coordinated the society’s work in support of rescheduling hydrocodone combination products from Schedule III to Schedule II to improve the safe and appropriate use of those therapies. In addition, she led development of policy that called on clinicians to increase efforts to combat prescription drug abuse while also ensuring patient access to needed pain therapies.
Reilly received her bachelor’s degree in pharmacy from Temple University in Philadelphia, Pennsylvania. She is currently enrolled in the master’s program in health and medical policy at George Mason University.
Public and private insurance plans use patient review and restriction (PRR) programs to encourage the safe use of opioids and other controlled substances. Through PRRs, insurers assign patients who are at risk for substance use disorder (SUD) to predesignated pharmacies and prescribers to obtain these drugs. Read More
Authorities today released Prince’s autopsy results, confirming that the renowned singer died from a prescription opioid overdose. Tragically, his cause of death is not rare: On April 21, Prince was just one of an estimated 52 Americans who lost their lives to an overdose of prescription pain relievers. Read More
On May 31, The Pew Charitable Trusts submitted a letter to the Substance Abuse and Mental Health Services Administration (SAMHSA), urging the agency to increase the cap for qualifying buprenorphine prescribers from 100 to 500 patients in order to expand access to medication-assisted treatment for opioid use disorder. Read More